SEC Form 4 · accession 0001209191-16-117158
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Grove Matsuoka
Officer — See Remarks
Period of report
May 3, 2016
Accepted (ET)
May 3, 2016 · 7:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.67 | May 3, 2016 | A | 145,000 | A | — | May 3, 2026 | Common Stock | 145,000 | 145,000 | D |
Explanation of responses
- F11/4 of the shares subject to this option shall vest and become exercisable on May 2, 2017, and the remainder shall thereafter vest in 36 equal monthly installments, such that this option is fully exercisable on May 2, 2020. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Remarks
Senior Vice President, Product Programs & Planning